Welcome to the 
(Video) Library

Physician Dr Saeed Mohammad


Meet real physicians and key experts who share their experiences and offer their perspectives on everything from patient diagnosis to treatment with LIVMARLI.

Watch physicians’ perspectives video

Physicians’ Perspectives on Pruritus

Listen in as Dr Jennifer Vittorio and Dr Saeed Mohammad reflect on their experiences treating patients with cholestatic pruritus.

Tyler, a person with Alagille syndrome


Hear from real patients and their families as they share their unique experiences—life before diagnosis, challenges before starting LIVMARLI, and the difference LIVMARLI is making in their lives.*

*Not all patients taking LIVMARLI will have the same experiences.

Watch the video of Finley

Meet Finley

Finley experienced multiple symptoms for months before finally getting diagnosed and starting LIVMARLI.

Watch the video of Téa

Meet Téa

Téa struggled with persistent itching and disrupted sleep until she started LIVMARLI.

Watch the video of Tyler

Meet Tyler

Tyler spent the first 10 years of his life battling constant itching and relying on ineffective treatments before finally finding relief.

Watch the video of Emma and Abby

Meet Emma and Abby

Emma and Abby share their young-adult perspectives on growing up with cholestatic pruritus and how LIVMARLI helped relieve their symptoms.

Watch the video of Téa and her doctor

Watch Téa Interview Dr Bass

Explore the patient experience through the eyes of an 8-year-old. Téa, currently taking LIVMARLI, chats with her beloved physician, Dr Bass, about life with Alagille syndrome and shares how doctors can better help patients like her.

Root Out
Excess Bile

Learn how LIVMARLI—the first FDA-approved treatment for cholestatic pruritus in Alagille syndrome—battles bile acid buildup.1

See How LIVMARLI Works

Encourage patients to download the Itch✓ app to help them track symptom patterns over time and generate customized reports to share at appointments.

Check Out the Itch✓ App

Mirum Access Plus assists both you and your patients at every turn, helping you navigate the payer approval process—and beyond—with ease.

Learn More About
Mirum Access Plus
Collapse icon

Important Safety Information


LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events (eg, variceal hemorrhage, ascites, or hepatic encephalopathy).

Warnings and Precautions

Hepatotoxicity: LIVMARLI treatment is associated with a potential for drug-induced liver injury. In the Alagille syndrome trial, treatment-emergent elevations of liver tests or worsening of liver tests occurred.

Obtain baseline liver tests and monitor during treatment. Liver-related adverse reactions and physical signs of hepatic decompensation should also be monitored. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Permanently discontinue LIVMARLI if a patient experiences the following: persistent or recurrent liver test abnormalities, clinical hepatitis upon rechallenge, or a hepatic decompensation event.

GI Adverse Reactions: Diarrhea and abdominal pain were reported as the most common adverse reactions. Monitor for dehydration and treat promptly. Consider reducing the dosage or interrupting dosing if a patient experiences persistent diarrhea or has diarrhea with bloody stool, vomiting, dehydration requiring treatment, or fever.

Fat-Soluble Vitamin Deficiency: Patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, and LIVMARLI may adversely affect absorption of FSV. If bone fractures or bleeding occur, consider interrupting LIVMARLI and supplement with FSVs. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.

Adverse Reactions

The most common adverse reactions are diarrhea, abdominal pain, vomiting, FSV deficiency, liver test abnormalities, and bone fractures.

Drug Interactions

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI. A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

Dosing Information

LIVMARLI should be taken 30 minutes before a meal. The provided oral dosing dispenser must be used to accurately measure the dose. Any remaining LIVMARLI should be discarded 100 days after first opening the bottle.